

Application No.: 10/019,570

Attorney Docket No.: 086748-2017

Filing Date: November 8, 2001

Response to Office Action (mailed December 16, 2003) faxed June 16, 2004

Page 2 of 12

Amendments to the Claims

Please amend claims 1, 8, 10 and 17 as indicated below in the listing of claims.

Listing of Claims

This listing of claims will replace all prior versions, and listings, of claims in the application:

1. (Currently amended) A device for assaying a fluid for the presence or absence of different analytes comprising:

(A) a base having adjacent slots therein of sufficient length for insertion of a test strip therein, wherein each slot is defined by (a) a floor, (b) raised walls depending upwardly from the floor to separate each adjacent slot from the next, and (c) at least one open end;

(B) a multiplicity of test strips having an upstream and a downstream end, wherein a single test strip is inserted into each slot of the base so the downstream end of each test strip protrudes out of the open end of each slot; and wherein each test strip has a test zone and a control zone therein, and each test zone contains a binder specific for a different analyte;

(C) a cover attached to the upwardmost surface of each raised wall of the slots of the base, wherein the cover retains the test strips within the slots and has a first transparent window formed therein through which the test zone and the control zone of each of the test strips can be viewed.

2. (Original) The device according to Claim 1 further comprising a cap for insertion over the protruding ends of the test strips.

3. (Original) The device according to Claim 1 further comprising a second transparent window formed within the cover through which the test strips can be viewed.

Application No.: 10/019,570

Attorney Docket No.: 086748-2017

Filing Date: November 8, 2001

Response to Office Action (mailed December 16, 2003) faxed June 16, 2004

Page 3 of 12

4. (Original) The device according to Claim 1 wherein each test strip has a test zone therein and each test zone contains a binder specific for a different analyte.

5. (Original) The device according to Claim 4 wherein each binder is specific for a different drug of abuse.

6. (Original) The device according to Claim 4 wherein each test zone is visible through the first transparent window of the cover.

7. (Original) The device according to Claim 4 wherein each test strip further comprises a label upstream of the test zone, which label identifies the analyte for which the binder is specific.

8. (Currently amended) The device according to Claim 3 or ~~and~~ Claim 7, wherein the label on the test strip is visible through the second transparent window of the cover.

9. (Original) The device according to Claim 4, further comprising test strips for determining the integrity of the fluid analyte sample.

10. (Currently amended) A device for assaying a fluid for the presence or absence of different analytes comprising:

(A) a base having adjacent slots therein of sufficient length for insertion of a test strip therein, wherein each slot is defined by (a) a floor, (b) raised walls depending upwardly from the floor to separate each adjacent slot from the next, and (c) at least one open end;

(B) a multiplicity of test strips having an upstream and a downstream end, wherein a single test strip is inserted into each slot of the base so the upstream end of each test strip protrudes out of the open end of each slot; and wherein each test strip has a test zone and a control zone therein, and each test zone contains a binder specific for a different analyte;

Application No.: 10/019,570 Attorney Docket No.: 086748-2017
Filing Date: November 8, 2001
Response to Office Action (mailed December 16, 2003) faxed June 16, 2004
Page 4 of 12

(C) a cover having (a) a first section attached to the upwardmost surface of each raised wall of the slots of the base, wherein the first section of the cover retains the test strips within the slots and has a first transparent window formed therein through which the test zone and the control zone of each of the test strips can be viewed, and (b) a second section enclosing the protruding ends of the test strips, the second section comprising:

- (i) a sample port formed through which fluid analyte sample may be applied to the protruding ends of the test strips; and,
- (ii) a floor opposing the sample port, the floor comprising a wall having a raised bar therein which defines a fluid reservoir beneath the sample port.

11. (Original) The device according to Claim 10 wherein the second section of the cover is removable from the first section of the cover.

12. (Original) The device according to Claim 10 further comprising a second transparent window formed within the cover through which the test strips can be viewed.

13. (Original) The device according to Claim 10 further comprising a multiplicity of test strips inserted into each slot of the base, wherein each test strip has a test zone therein and each test zone contains a binder specific for a different analyte.

14. (Original) The device according to Claim 13 wherein each binder is specific for a different drug of abuse.

15. (Original) The device according to Claim 13 wherein each test zone is visible through the first transparent window of the cover.

16. (Original) The device according to Claim 13 wherein each test strip further comprises a label downstream of the test zone, which label identifies the analyte for which the binder is specific.

Application No.: 10/019,570

Attorney Docket No.: 086748-2017

Filing Date: November 8, 2001

Response to Office Action (mailed December 16, 2003) faxed June 16, 2004

Page 5 of 12

17. (Currently amended) The device according to Claim 12 ~~or and~~ Claim 16, wherein the label on the test strip is visible through the second transparent window of the cover.

18. (Original) The device according to Claim 5 wherein the drug of abuse is selected from the group consisting of methamphetamine, opiates/morphine, marijuana/tetrahydrocannabinol, amphetamine, cocaine/benzoylecgonine, methadone, PCP, barbituate, trichloroacetic acid and benzodiazepine.

19. (Original) The device according to Claim 14 wherein the drug of abuse is selected from the group consisting of methamphetamine, opiates/morphine, marijuana/tetrahydrocannabinol, amphetamine, cocaine/benzoylecgonine, methadone, PCP, barbituate, trichloroacetic acid and benzodiazepine.

20. (Original) The device according to Claim 13, further comprising test strips for determining the integrity of the fluid analyte sample.

21. (Withdrawn).

22. (Original) A method for assaying a fluid analyte sample for the presence or absence of multiple analytes, the method comprising:

(A) immersing the protruding ends of the test strips of the device of Claim 1 into the fluid analyte sample; and,

(B) reading the assay results through the first transparent window of the cover.

23. (Withdrawn).

Application No.: 10/019,570

Attorney Docket No.: 086748-2017

Filing Date: November 8, 2001

Response to Office Action (mailed December 16, 2003) faxed June 16, 2004

Page 6 of 12

24. (Original) A method for assaying a fluid analyte sample for the presence or absence of multiple analytes, the method comprising:

- (A) applying fluid analyte sample through the sample port of the cover of the device of Claim 10 to contact the test strips of the device; and,
- (B) reading the assay results through the first transparent window of the cover.

25. (Withdrawn).